Anneclaire J De Roos1, Otoniel Martínez-Maza, Keith R Jerome, Dana K Mirick, Kenneth J Kopecky, Margaret M Madeleine, Larry Magpantay, Kerstin L Edlefsen, Andrea Z Lacroix. 1. Authors' Affiliations: Department of Environmental and Occupational Health, Drexel University School of Public Health, Philadelphia, Pennsylvania; Division of Public Health Sciences and Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; Department of Epidemiology, School of Public Health and Department of Laboratory Medicine, University of Washington, Seattle, Washington; Departments of Obstetrics & Gynecology, and Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine at UCLA; Jonsson Comprehensive Cancer Center; UCLA AIDS Institute; and Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, California.
Abstract
BACKGROUND: We hypothesized that poor control of Epstein-Barr virus (EBV) infection, leading to reactivation of the virus, increases the risk of non-Hodgkin lymphoma (NHL) in the general population of primarily immunocompetent persons. METHODS: We conducted a case-control study nested within the Women's Health Initiative Observational Study cohort in which we measured antibodies to EBV antigens [immunoglobulin G (IgG) to viral capsid antigen (VCA), nuclear antigen (EBNA1), and early antigen-diffuse (EA-D)] and EBV DNA load in prediagnostic samples of 491 B-cell NHL cases and 491 controls. RESULTS: We found no association with established EBV infection, based on seropositivity for VCA. Seropositivity for EBNA1 was associated with decreased risk of B-cell NHL, overall [OR = 0.5; 95% confidence interval (CI), 0.3-0.8] and for each of the histologic subtypes examined. Increased risk of chronic lymphocytic leukemia (CLL) and related subtypes was observed with higher levels of EBV DNA and antibody to EA-D, both markers reflective of reactivation. These associations were strongest for cases with the shortest time interval between blood draw and diagnosis. CONCLUSIONS: In balance, these results do not provide strong evidence of EBV playing a causal role in B-cell NHL in general population women. The associations we observed may reflect increased risk of NHL with underlying immune impairment or could be due to reverse causation. IMPACT: Further characterization of the subtype-specific association with CLL is warranted. Exclusion of cases with preclinical disease markers (such as monoclonal B-lymphocytosis for CLL) may help rule out reverse causation in future studies.
BACKGROUND: We hypothesized that poor control of Epstein-Barr virus (EBV) infection, leading to reactivation of the virus, increases the risk of non-Hodgkin lymphoma (NHL) in the general population of primarily immunocompetent persons. METHODS: We conducted a case-control study nested within the Women's Health Initiative Observational Study cohort in which we measured antibodies to EBV antigens [immunoglobulin G (IgG) to viral capsid antigen (VCA), nuclear antigen (EBNA1), and early antigen-diffuse (EA-D)] and EBV DNA load in prediagnostic samples of 491 B-cell NHL cases and 491 controls. RESULTS: We found no association with established EBV infection, based on seropositivity for VCA. Seropositivity for EBNA1 was associated with decreased risk of B-cell NHL, overall [OR = 0.5; 95% confidence interval (CI), 0.3-0.8] and for each of the histologic subtypes examined. Increased risk of chronic lymphocytic leukemia (CLL) and related subtypes was observed with higher levels of EBV DNA and antibody to EA-D, both markers reflective of reactivation. These associations were strongest for cases with the shortest time interval between blood draw and diagnosis. CONCLUSIONS: In balance, these results do not provide strong evidence of EBV playing a causal role in B-cell NHL in general population women. The associations we observed may reflect increased risk of NHL with underlying immune impairment or could be due to reverse causation. IMPACT: Further characterization of the subtype-specific association with CLL is warranted. Exclusion of cases with preclinical disease markers (such as monoclonal B-lymphocytosis for CLL) may help rule out reverse causation in future studies.
Authors: Hans Helmut Niller; Daniel Salamon; Karin Ilg; Anita Koroknai; Ferenc Banati; Fritz Schwarzmann; Hans Wolf; Janos Minarovits Journal: Med Hypotheses Date: 2004 Impact factor: 1.538
Authors: Ola Landgren; Maher Albitar; Wanlong Ma; Fatima Abbasi; Richard B Hayes; Paolo Ghia; Gerald E Marti; Neil E Caporaso Journal: N Engl J Med Date: 2009-02-12 Impact factor: 91.245
Authors: Carlo Visco; Erika Falisi; Ken H Young; Michela Pascarella; Omar Perbellini; Giuseppe Carli; Elisabetta Novella; Davide Rossi; Ilaria Giaretta; Chiara Cavallini; Maria Teresa Scupoli; Anita De Rossi; Emanuele Stefano Giovanni D'Amore; Mario Rassu; Gianluca Gaidano; Giovanni Pizzolo; Achille Ambrosetti; Francesco Rodeghiero Journal: Oncotarget Date: 2015-07-30
Authors: Ewelina Grywalska; Michał Mielnik; Martyna Podgajna; Anna Hymos; Jarosław Ludian; Agnieszka Rolińska; Krzysztof Gosik; Wojciech Kwaśniewski; Barbara Sosnowska-Pasiarska; Jolanta Smok-Kalwat; Marcin Pasiarski; Agnieszka Stelmach-Gołdyś; Stanisław Góźdź; Jacek Roliński Journal: Cancers (Basel) Date: 2022-01-28 Impact factor: 6.639
Authors: Unhee Lim; Jonathan M Kocarnik; William S Bush; Tara C Matise; Christian Caberto; Sungshim Lani Park; Christopher S Carlson; Ewa Deelman; David Duggan; Megan Fesinmeyer; Christopher A Haiman; Brian E Henderson; Lucia A Hindorff; Laurence N Kolonel; Ulrike Peters; Daniel O Stram; Maarit Tiirikainen; Lynne R Wilkens; Chunyuan Wu; Charles Kooperberg; Loïc Le Marchand Journal: PLoS One Date: 2014-03-05 Impact factor: 3.240
Authors: Ewelina Grywalska; Marcin Pasiarski; Barbara Sosnowska-Pasiarska; Paweł Macek; Agnieszka Rolińska; Marzena Samardakiewicz; Jarosław Ludian; Stanisław Góźdź; Jacek Roliński Journal: Cancer Manag Res Date: 2019-08-12 Impact factor: 3.989